Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NBY's Cash to Debt is ranked higher than
90% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. NBY: No Debt )
NBY' s 10-Year Cash to Debt Range
Min: 12.67   Max: No Debt
Current: No Debt

Equity to Asset 0.68
NBY's Equity to Asset is ranked higher than
76% of the 754 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. NBY: 0.68 )
NBY' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.83
Current: 0.68

-0.32
0.83
Interest Coverage No Debt
NBY's Interest Coverage is ranked higher than
80% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.25 vs. NBY: No Debt )
NBY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -3.40
M-Score: 7.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -777.82
NBY's Operating margin (%) is ranked lower than
54% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.92 vs. NBY: -777.82 )
NBY' s 10-Year Operating margin (%) Range
Min: -445.38   Max: 17.47
Current: -777.82

-445.38
17.47
Net-margin (%) -717.43
NBY's Net-margin (%) is ranked lower than
54% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.26 vs. NBY: -717.43 )
NBY' s 10-Year Net-margin (%) Range
Min: -461.37   Max: 17.2
Current: -717.43

-461.37
17.2
ROE (%) -171.69
NBY's ROE (%) is ranked lower than
54% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.33 vs. NBY: -171.69 )
NBY' s 10-Year ROE (%) Range
Min: -699.25   Max: 26.07
Current: -171.69

-699.25
26.07
ROA (%) -101.46
NBY's ROA (%) is ranked lower than
56% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.07 vs. NBY: -101.46 )
NBY' s 10-Year ROA (%) Range
Min: -426.46   Max: 17.13
Current: -101.46

-426.46
17.13
ROC (Joel Greenblatt) (%) -2371.98
NBY's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.20 vs. NBY: -2371.98 )
NBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2673.41   Max: 139.97
Current: -2371.98

-2673.41
139.97
Revenue Growth (%) -40.20
NBY's Revenue Growth (%) is ranked lower than
52% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NBY: -40.20 )
NBY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 36.1
Current: -40.2

0
36.1
EBITDA Growth (%) 30.50
NBY's EBITDA Growth (%) is ranked higher than
91% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. NBY: 30.50 )
NBY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 58.2
Current: 30.5

0
58.2
EPS Growth (%) 32.60
NBY's EPS Growth (%) is ranked higher than
89% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. NBY: 32.60 )
NBY' s 10-Year EPS Growth (%) Range
Min: -33.1   Max: 56.5
Current: 32.6

-33.1
56.5
» NBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBY Guru Trades in

Q2 2013

NBY Guru Trades in Q2 2013

Jim Simons 15,200 sh (New)
» More
Q3 2013

NBY Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q2 2014

NBY Guru Trades in Q2 2014

Jim Simons 39,500 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.40
NBY's P/B is ranked higher than
67% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.39 vs. NBY: 4.40 )
NBY' s 10-Year P/B Range
Min: 1.76   Max: 13.86
Current: 4.4

1.76
13.86
EV-to-EBIT -1.78
NBY's EV-to-EBIT is ranked lower than
51% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.17 vs. NBY: -1.78 )
NBY' s 10-Year EV-to-EBIT Range
Min: 14.9   Max: 81.4
Current: -1.78

14.9
81.4
Current Ratio 6.39
NBY's Current Ratio is ranked higher than
92% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. NBY: 6.39 )
NBY' s 10-Year Current Ratio Range
Min: 1.34   Max: 10.63
Current: 6.39

1.34
10.63
Quick Ratio 6.28
NBY's Quick Ratio is ranked higher than
92% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NBY: 6.28 )
NBY' s 10-Year Quick Ratio Range
Min: 1.34   Max: 10.63
Current: 6.28

1.34
10.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.57
NBY's Price/Net Cash is ranked higher than
96% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NBY: 5.57 )
NBY' s 10-Year Price/Net Cash Range
Min: 2.65   Max: 15.64
Current: 5.57

2.65
15.64
Price/Net Current Asset Value 5.20
NBY's Price/Net Current Asset Value is ranked higher than
93% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NBY: 5.20 )
NBY' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 15.64
Current: 5.2

2.3
15.64
Price/Tangible Book 4.33
NBY's Price/Tangible Book is ranked higher than
74% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. NBY: 4.33 )
NBY' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 12.29
Current: 4.33

1.9
12.29
Earnings Yield (Greenblatt) 1.90
NBY's Earnings Yield (Greenblatt) is ranked higher than
58% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. NBY: 1.90 )
NBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 6.7
Current: 1.9

1.2
6.7
Forward Rate of Return (Yacktman) -30.98
NBY's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. NBY: -30.98 )
NBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -30.98

-156.4
-21.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
NovaBay Pharmaceuticals, Inc., a Delaware corporation was incorporated on January 19, 2000. The Company was originally incorporated in California as NovaCal Pharmaceuticals, Inc. and subsequently changed its name to NovaBay Pharmaceuticals, Inc. The Company is a clinical-stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products namely Aganocide Compounds and NeutroPhase. The Aganocide Compounds led by auriclosene (NVC-422),are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. The Company focuses in three large therapeutic markets namely Dermatology, Ophthalmology, and Urology. The Company also develops another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. Its competitors are Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. NovaBay, NovaBay Pharma, AgaNase, Aganocide, AgaDerm and NeutroPhase are registered U.S. trademarks of the Company. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries. In the U.S., the FDA regulates drugs and medical devices under the Federal Food, Drug, and Cosmetic Act and the agency's implementing regulations.
» More Articles for NBY

Headlines

Articles On GuruFocus.com
Own it Feb 29 2012 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results Aug 14 2009 

More From Other Websites
NovaBay Receives First Large NeutroPhase Order From China Pioneer Pharma Sep 25 2014
NovaBay Receives First Large NeutroPhase Order From China Pioneer Pharma Sep 25 2014
NovaBay Pharmaceuticals Creates Optometry Advisory Board Sep 18 2014
NovaBay Pharmaceuticals Will Feature i-Lid Cleanser for the First Time at Vision Expo West Sep 16 2014
Hispanic Heroes Honored in Fight Against "Flesh-Eating" Disease Sep 15 2014
Center Director of Omni Eye Surgery in New York City Describes a Promising New Product for the... Sep 09 2014
NovaBay Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Healthcare Conference Sep 05 2014
China’s Food and Drug Administration has Cleared NovaBay’s NeutroPhase Skin and Wound Cleanser... Sep 03 2014
China’s Food and Drug Administration has Cleared NovaBay’s NeutroPhase Skin and Wound Cleanser... Sep 03 2014
NovaBay Pharmaceuticals Adds Five Top Ophthalmologists to its Ophthalmic Advisory Board Aug 28 2014
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser Across the U.S. Aug 25 2014
Why NovaBay Pharmaceuticals (NBY) Stock Plummeted to a One-Year Low Today Aug 20 2014
Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' Aug 20 2014
NovaBay Announces Results of NVC-422 Phase 2 for Viral Conjunctivitis Aug 20 2014
NovaBay Announces Results of NVC-422 Phase 2 for Viral Conjunctivitis Aug 20 2014
National Necrotizing Fasciitis Foundation Warns Watch Out For Vibrio Infections Aug 12 2014
NOVABAY PHARMACEUTICALS, INC. Financials Aug 09 2014
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update Jul 31 2014
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Jul 31 2014
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease Jul 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK